- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| Di | BELITE BIO, INC - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 26.03. | Belite Bio stock target raised to $80 at Benchmark | 1 | Investing.com | ||
| 21.03. | BELITE BIO, INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 18.03. | Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials | 2 | Benzinga.com | ||
| 18.03. | Belite Bio stock holds $100 target post-results | 1 | Investing.com | ||
| 17.03. | Belite Bio GAAP EPS of -$0.32 misses by $0.01 | 1 | Seeking Alpha | ||
| 17.03. | Belite Bio, Inc Q4 Loss Increases, Misses Estimates | 1 | RTTNews | ||
| 17.03. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 17.03. | Belite Bio, Inc: Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | 91 | GlobeNewswire (Europe) | Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in adolescent Stargardt 1 (STGD1) subjects, proceed without... ► Artikel lesen | |
| 17.03. | Belite Bio, Inc: Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website | 1 | GlobeNewswire (USA) | ||
| 11.03. | Belite Bio, Inc: Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results | 1 | GlobeNewswire (USA) | ||
| 27.02. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 27.02. | Belite Bio, Inc: Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects | 116 | GlobeNewswire (Europe) | An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the sample size at 104 subjects following a planned... ► Artikel lesen | |
| 06.02. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.02. | Belite Bio to raise $15M via direct offering | 4 | Seeking Alpha | ||
| 06.02. | Belite Bio, Inc: Belite Bio Announces Registered Direct Offering of $15 Million | 1 | GlobeNewswire (USA) | ||
| 27.01. | Belite Bio files for automatic mixed securities shelf | 1 | Seeking Alpha | ||
| 14.11.24 | Belite Bio stock soars to all-time high of $84.2 amid robust gains | 1 | Investing.com | ||
| 14.11.24 | Belite Bio-Aktie erreicht Rekordhoch von 84,20 US-Dollar | 2 | Investing.com Deutsch | ||
| 12.11.24 | Belite Bio, Inc: Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | 169 | GlobeNewswire (Europe) | Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects... ► Artikel lesen |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,618 | -0,06 % | Sangamo-Aktie schießt hoch: Deal mit Eli Lilly - die Details | Mit einem Plus von gut 20 Prozent gehört die Aktie der Biotech-Gesellschaft Sangamo Therapeutics am Freitag zu den wenigen Aktien an der Börse, die mit einem sehr deutlichen Kursaufschlag gehandelt... ► Artikel lesen | |
| ARGENX | 524,60 | +0,04 % | argenx SE: argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy | VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringeSelf-injection provides gMG and CIDP patients with flexibility... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 2,280 | -0,87 % | Amended: Protalix Annual Earnings Fall | JERUSALEM (dpa-AFX) - (Amended: Recasting the story to correct the period, revenue)Protalix BioTherapeutics, Inc. (PLX), a biopharmaceutical company, Monday reported a decline in earnings for... ► Artikel lesen | |
| ENZO BIOCHEM | 0,298 | +17,32 % | Enzo Biochem, Inc.: Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX | FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company") today announced its intention to voluntarily delist its common stock from The New York... ► Artikel lesen | |
| QUANTERIX | 5,150 | 0,00 % | Quanterix Provides Update on Financial Performance | BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced selected preliminary... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 2,700 | -0,37 % | Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study | Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants... ► Artikel lesen |
BELITE BIO INC ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,39 % bei einem Aktienkurs von 49,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.
